Scienture Reports Record Revenue Growth and Expands Gross Margin in 2025

Scienture Holdings reported a 216% increase in net revenue to $431,609 in 2025, with a gross margin expansion of 7,240 basis points to 76.8%. The company secured multiple PBM-led GPO rebate agreements, expanded U.S. access to over 2,500 healthcare institutions, and achieved formulary inclusion with major national health plans for Arbli. Scienture also established a strategic collaboration with BlinkRx and received Orange Book-listable patents for REZENOPY and Arbli.